Alembic Pharma
What captured our attention
Alembic Pharma emerged as a standout with the nation's highest R&D investment in the pharmaceutical sector. Their robust product pipeline drove an impressive 40% year-on-year expansion in the US market from FY15-20. Additionally, substantial investments in complex generics (INR30bn) reinforced its dominant market position.
Valuation Discrepancy Insights
At the outset, the company traded at a modest 13x PE (FY22E) compared to peers at over 18x. The consensus failed to grasp the potential of US supply shortages and the impact of increased capital expenditure.
Monarch Networth's Value-Added Contribution
We distinguish ourselves as one of the select brokers covering Alembic Pharma. Our clients benefitted from privileged access to senior management, facilitating informed investment decisions.
